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Abstract The major green tea catechin, (3)-epigallocatechin-
3-O-gallate (EGCG), has a suppressive e¡ect on the expression
of the high-a⁄nity IgE receptor FcORI, which is key molecule in
the IgE-mediated allergic reactions. Here we show that EGCG
binds to the cell surface and highly associates with plasma mem-
brane microdomains, lipid rafts, on the human basophilic
KU812 cells. The disruption of these lipid rafts caused a reduc-
tion of the amount of raft-associated EGCG and the FcORI-
suppressive e¡ect of EGCG. We also found that EGCG has
an ability to inhibit the phosphorylation of the extracellular
signal-regulated kinase1/2 (ERK1/2) and that the ERK1/2 spe-
ci¢c inhibitor also reduced FcORI expression. Moreover, the
inhibitory e¡ect elicited by EGCG on ERK1/2 was prevented
by disruption of rafts. Thus, these results suggest that the in-
teraction between EGCG and the lipid rafts is important for
EGCG’s ability to downregulate FcORI expression, and
ERK1/2 may be involved in this suppression signal.
4 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The high-a⁄nity IgE receptor FcORI is expressed on the
surface of e¡ector cells, such as mast cells and basophils.
Crosslinking of allergen speci¢c IgE bound with FcORI by a
multivalent antigen induces activation of these cells and re-
sults in the secretion of allergic mediators as well as the in-
duction of cytokine gene transcription [1]. Therefore, FcORI
plays a central role in the induction and maintenance of IgE-
mediated allergic responses such as atopic dermatitis, bron-
chial asthma, allergic rhitis, and food allergy. The FcORI mol-
ecule on these cells is a tetrameric structure of one K chain,
one L chain, and two disul¢de-linked Q chains. In addition, a
trimeric form of FcORI which lacks the L chain is found in
human. Among the three subunits forming FcORI, the K chain
is the speci¢c component of FcORI that mostly extends out to
the extracellular region and directly binds to IgE. Analysis of
K chain-de¢cient mice demonstrated that IgE was unable to
bind to the cell surface of mast cells, thereby inabling the
induction of degranulation through IgE binding [2]. Thus, it
is expected that the downregulation of FcORI expression in
mast cells and basophils may lead to the attenuation of the
IgE-mediated allergic symptoms.
We recently found that the major catechin in green tea,
(3)-epigallocatechin-3-O-gallate (EGCG), was able to de-
crease FcORI expression and negatively regulate basophil ac-
tivation [3,4]. The biological and pharmacological properties
of EGCG, including anti-oxidative and cancer-preventive ef-
fects, have been reported [5^7]. The modulation of epidermal
growth factor receptor function, protein kinase C activation,
mitogen-activated protein kinase (MAPK) cascades were
thought to be the most interesting targets to evaluate the
e¡ect of EGCG [8^10]. It has been suggested that EGCG
and its derivatives exhibit biological activities through inter-
actions with the cellular membranes [11]. The study, using the
liposome system, on the interaction of tea catechins with the
lipid bilayers implicates that the a⁄nity of catechins for the
lipid bilayers may be responsible for various kinds of actions
[12]. Further investigation about the cellular interaction of
EGCG may contribute to the elucidation of the mechanism
of how EGCG can decrease FcORI expression.
Recently, plasma membrane microdomains referred to as
‘lipid rafts’ have received much attention as potential regula-
tors and organizing centers for signal transduction and mem-
brane tra⁄c pathways [13]. These microdomains have been
characterized as sphingolipid/cholesterol-rich domains in the
plasma membranes. Lipid rafts have also been shown to in-
teract with various kinds of extracellular factors including
cytokines and growth factors, neuroproteins, and viruses
[14^17]. However, little is known about the interaction of
these microdomains with low molecular compounds such as
tea catechins.
In this report, we have shown that EGCG binds to the cell
surface and interacts with the plasma membrane microdo-
main, lipid rafts in the human basophilic KU812 cells. In
addition, our results suggested that the inhibition of extracel-
lular signal-regulated kinase1/2 (ERK1/2) phosphorylation,
which is the member of MAPK family, is involved in the
ability of EGCG to suppress the expression of FcORI, and
further lipid rafts may play an important role in downregula-
tory signaling.
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2. Materials and methods
2.1. Reagents
EGCG was purchased from Kurita Water Industries LTD (Tokyo,
Japan). Protein A Sepharose beads were purchased from Amersham
Pharmacia Biotech (UK). Mouse anti-human FcORI K chain antibody
CRA-1 was obtained from Kyokuto seiyaku (Tokyo, Japan). Mouse
IgG2b, used as negative control, was bought from Dako (A/S, Den-
mark). Fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse
IgG antibody was purchased from Protos Immunoresearch (Burlin-
game, CA, USA). Both anti-phosphorylated p38 MAPK and c-jun N-
terminal kinase (JNK) antibodies were purchased from Cell Signaling
Technology, Inc. (Beverly, MA, USA). Mouse anti-phosphorylated
ERK1/2 antibody and rabbit anti-ERK1/2 antibody were obtained
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Anti-
mouse IgG antibody, horseradish peroxidase (HRP)-conjugated anti-
mouse IgG antibody, and HRP-conjugated anti-rabbit antibody were
obtained from Zymed Laboratories, Inc. (San Francisco, CA, USA)
and ICN Pharmaceuticals, Inc. (Aurora, OH, USA), respectively.
Methyl-L-cyclodextrin (MLCD), FITC-conjugated cholera toxin B
(CTXB), and HRP-conjugated CTXB were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). MAPK speci¢c inhibitors,
PD98059, SB203580 and SP600125, were obtained from Biomol Re-
search Laboratories, Inc. (Plymouth Meeting, PA, USA).
2.2. Cell culture and stimulation
KU812 cells were obtained from the Japanese Cancer Research
Resources Bank (Tokyo, Japan) and were cultured in serum-free
RPMI-1640 medium with or without EGCG or MAPK speci¢c in-
hibitors. MAPK inhibitors were dissolved in dimethyl sulfoxide
(DMSO), with the ¢nal concentration of DMSO being 0.1%. This
concentration of DMSO had no e¡ect in any of the experiments.
For the cholesterol depletion study, cells were treated in a lipid-free
medium with 5 mM MLCD for 45 min at 37‡C. After washing, the
cells were used in the following experiments. Cellular cholesterols were
measured by using a commercial kit (Wako Pure Chemical Industries,
Osaka, Japan). We checked the cell viability of KU812 cells treated
with or without MLCD by trypan-blue exclusion methods.
2.3. Flow cytometric analysis of the cell surface expression of FcORI
The cell surface expression of FcORI was assessed by £ow cytome-
try as previously described [3]. In brief, cells were incubated with the
anti-FcORI K chain antibody CRA-1. Then cells were exposed to the
FITC-conjugated anti-mouse IgG and subjected to £ow cytometry
(FACSCalibur; Becton Dickinson, Sunnyvale, CA, USA). As a neg-
ative control, the mouse subclass-matched IgG2b antibody was used.
The extent of FcORI expression is represented as the mean £uores-
cence intensity of CRA-1, and the value is indicated in each panel
(Fig. 3). The vertical line in the ¢gure indicates the peak point for
CRA-1 in non-treated cells.
2.4. Binding analysis using surface plasmon resonance (SPR) biosensor
Analysis of the interaction between catechin derivatives and KU812
cells was performed using the SPR biosensor SPR670 (Nippon Laser
and Electronics Lab., Nagoya, Japan). KU812 cells were immobilized
on the sensor chip and then this chip was equilibrated in SPR running
bu¡er, phosphate-bu¡ered saline (pH 7.4, 30 Wl min31). EGCG was
diluted at 0 or 50 WM in SPR running bu¡er in 60 Wl injection vol-
umes and at a £ow rate of 30 Wl min31. Binding was measured at 25‡C
for 2 min, followed by dissociation. The value of the angle in Fig. 2
corresponded with the binding strength.
2.5. Puri¢cation of raft fractions
After treatment of KU812 cells with or without 50 WM EGCG for
24 h, raft fractions were prepared by cell lysis using 1% Triton X-100
followed by sucrose gradient fractionation as described previously
[18]. One-ml fractions were collected from the top of the gradient
[designated fractions number 1 (top) through 12 (bottom)]. For ex-
periments that involved pooling of fractions, low-buoyant density
fractions 4^6 were designated raft fractions and high-buoyant density
fractions 11^12 were designated non-raft fractions. Protein concentra-
tion of each fraction was determined using the BCA protein assay kit
(Pierce, Rockford, IL, USA). Pooled raft and non-raft fractions were
then internally normalized for protein content.
2.6. Quantitation of EGCG
The level of EGCG in raft and non-raft fractions was determined
by high-performance liquid chromatography (HPLC) with a coulo-
metric array detector (Model 5600 CoulArray, ESA Inc., Chelms-
ford). In brief, 200 Wg of raft and non-raft fractions were extracted
by ethyl acetate twice. The combined ethyl acetate solutions were
added to a 20% ascorbic acid solution, and dried under nitrogen
gas and then redissolved in a 50% acetonitrile aqueous solution.
The resultant solution was injected onto the HPLC with TSK gel
ODS 80Ts reversed-phase column (4.6U250 mm, Tosoh, Tokyo, Ja-
pan). The column was eluted at 30‡C with 0.1 M NaH2PO4 bu¡er
(pH 2.5) containing 0.1 mM EDTAW2Na^acetonitrile (87:13) at a £ow
rate of 0.6 ml min31. The eluent was monitored electrochemically at
an applied potential of +660 mV versus Ag/AgCl.
2.7. Immunoprecipitation and immunoblot analysis
For immunoprecipitation, KU812 cells were cultured with 10 WM
PD98059 or 25 WM EGCG for 24 h under serum-free conditions, and
then the cells were lysed as previously described [3]. Whole cell lysates
were incubated with protein A Sepharose beads bound with the anti-
FcORI K chain antibody CRA-1 for 4 h at 4‡C. The beads were
resuspended in sodium dodecyl sulfate^polyacrylamide gel electropho-
resis (SDS^PAGE) bu¡er. After centrifugation, supernatants were
subjected to immunoblot analysis. The immunoprecipitates were
loaded onto an 8% SDS^PAGE gel, and electrophoresis was done
under reducing conditions. The samples were then electrotransferred
onto a nitrocellulose membrane. The membrane was probed for the
FcORI K chain using the anti-FcORI K chain antibody CRA-1. The
secondary antibody used was the HRP-conjugated anti-mouse IgG,
and detection was done using the ECL kit (Amersham Pharmacia
Biotech). For examination of MAPK, the cells were treated with 25
WM EGCG or 10 WM PD98059 for 3 h, and then lysed. The whole
lysate were resuspended in SDS^PAGE bu¡er and subjected to 10%
SDS^PAGE and immunoblotted using the anti-phosphorylated
ERK1/2, p38 MAPK, or the JNK antibody and the HRP-conjugated
anti-rabbit IgG antibody. For detection of total ERK1/2, the same
¢lter was blotted again with anti-ERK1/2 antibody. The detection of
L-actin was simultaneously performed as a gel loading control. To
con¢rm the location of lipid rafts in recovered and pooled sucrose
gradient fractions, both low- and high-buoyant density fractions were
subjected to 10% SDS^PAGE and immunoblotted using CTXB sub-
unit conjugated to HRP and ECL systems.
2.8. Reverse transcription-polymerase chain reaction (RT-PCR) and
Southern blot analysis
Total RNA was isolated using the TRIZol reagent (Invitrogen,
Carlsbad, CA, USA) and was reverse transcribed. The resultant
cDNA samples were subjected to 13 cycles of PCR ampli¢cation in
the presence of speci¢c sense and antisense primers. Human glycer-
aldehyde-3-phosphate dehydrogenase (G3PDH) cDNA was ampli¢ed
as an internal control. Temperatures were 94‡C for denaturation,
60‡C for annealing, and 72‡C for polymerizations. Sequences for
the PCR primers are as follows: for the FcORI K chain: sense 5P-
CTTAGGATGTGGGTTCAGAAGT-3P, and antisense 5P-GACAG-
TGGAGAATACAAATGTCA-3P ; for the FcORI Q chain: sense 5P-
TAGGGCCAGCTGGTGTTAATGGCA-3P, and antisense 5P-GAT-
GATTCCAGCAGTGGTCTTGCT-3P ; for G3PDH: sense 5P-GCT-
CAGACACCATGGGGAAGGT-3P, and antisense 5P-GTGGTGC-
AGGAGGCATTGCTGA-3P. The ampli¢ed PCR products were
subjected to agarose gel electrophoresis, transferred to a Hybond-
Nþ membrane (Amersham Pharmacia Biotech) and hybridized with
£uorescein-labeled probes speci¢c for FcORI K and Q chains and
G3PDH. The hybridized probe was detected using the Gene Images
detection kit (Amersham Pharmacia Biotech).
3. Results
3.1. Interaction between EGCG and plasma membrane
microdomain lipid rafts
To elucidate which interactions of EGCG with the cells was
responsible for FcORI-suppressive e¡ect, the involvement of
plasma membrane microdomains, lipid rafts, on EGCG func-
tion was investigated. The role of lipid rafts in FcORI-ex-
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pressed cells such as basophils has mostly been analyzed in rat
basophilic cell line, RBL-2H3, and the cells have been shown
to contain rafts as de¢ned by the resistance of pool of mem-
brane components to extraction by cold Triton X-100 [19^21].
Thus, human basophilic KU812 cells were lysed using cold
Triton X-100 followed by a sucrose gradient centrifugation.
The low- and high-buoyant density fractions were separately
pooled and designated as raft and non-raft fractions, respec-
tively. Because RBL-2H3 cells have been known to express the
raft component such as GM1 ganglioside and CTXB subunit
has been used to detect this GM1 [20,22], both fractions were
analyzed by CTXB subunit blotting. Fig. 1A shows that the
raft marker, GM1 ganglioside, was indeed recovered in raft
fraction, demonstrating that this fraction does contain lipid
rafts isolated from KU812 cells. We also con¢rmed that the
level of GM1 was not a¡ected upon a 24-h treatment with
EGCG in both fractions. In addition, EGCG did not a¡ect
the cellular level of GM1 over an incubation of 24 h (data not
shown). For elucidating the interaction of EGCG with the
lipid rafts, the amount of EGCG in the lipid rafts was directly
measured by HPLC analysis. The retention time of EGCG
was 33 min, and a EGCG peak was not observed in either
the raft or non-raft fractions from the cells treated without
EGCG (Fig. 1B). On the other hand, in both fractions from
EGCG-treated cells, a EGCG peak at the retention time of 33
min was detected. Interestingly, the level of EGCG in the raft
fraction was higher than the non-raft fraction, indicating that
EGCG does not homogenously bind to the membrane of the
cells, but interacts with the cells in a heterogeneous fashion.
This suggests that these lipid rafts may play a possible role in
the interaction of EGCG with the cells.
3.2. E¡ect of raft integrity on EGCG binding
To explore a potential role of lipid rafts in EGCG binding,
a study of raft integrity was performed using MLCD, a cho-
lesterol-removing agent that disturbs raft function [23]. It has
been reported that the treatment with 5 mM MLCD for 30 or
45 min led to 60% extraction of cellular cholesterol in RBL-
2H3 cells [19,24]. Treatment with 1 mM MLCD for 45 min
demonstrated a slight but signi¢cant decrease in the amount
of total cholesterol in KU812 cells (Fig. 2A). At a concentra-
tion of 5 mM, a reduction of 50% was seen. None of the doses
used a¡ected cell viability. The cholesterol lowering e¡ect of
MLCD was sustained for a period of at least 24 h (data not
shown). Because a raft integrity defect has been known to be
induced by a decrease in the amount of cellular cholesterol,
these ¢ndings may demonstrate that a raft integrity defect was
sustained within 24 h after MLCD treatment.
For investigating the e¡ect of lipid rafts disruption on the
interaction of EGCG with KU812 cells, we measured the cell
surface binding of EGCG to the MLCD-pretreated KU812
cells using a SPR biosensor. This SPR technique has been
increasingly used for a real-time analyses of the binding be-
tween solubilized molecules and molecules immobilized on the
surface of a biosensor chip without any labeling by changes in
the refractive index of a biospeci¢c surface [25]. In this bind-
ing analysis, the SPR signal has a characteristic behavior as
Fig. 1. HPLC chromatograms of EGCG in raft and non-raft frac-
tions isolated from KU812 cells. A: The cells treated with or with-
out EGCG were lysed with cold 1% Triton X-100 followed by a su-
crose gradient centrifugation. The low-buoyant density fractions
were designated raft fractions and the high-buoyant density frac-
tions were designated non-raft fractions. These fractions were sub-
jected to SDS^PAGE and transferred to nitrocellulose membranes,
and GM1-containing lipid rafts were determined using CTXB sub-
unit conjugated to HRP. B: Each fraction mentioned above was
subjected to HPLC analysis, and the chromatograms are shown.
The retention time for EGCG was con¢rmed by using the EGCG
standard.
Fig. 2. E¡ect of cholesterol depletion on the interaction between
EGCG and KU812 cells. A: KU812 cells were treated with MLCD
at the indicated concentrations for 45 min. Then, the total cellular
cholesterol amount and cell viability were measured. Each data val-
ue is expressed as meanVS.D. (n=3). Values are shown as relative
to 0 mM data (%) and asterisk marks denote signi¢cant di¡erences
from the control at each condition at *P6 0.05, **P6 0.01, and
***P6 0.001, respectively. Data is presented as the relative choles-
terol amount or cell viability to the control value. B: KU812 cells
were pretreated with or without MLCD, and then were ¢xed on the
sensor chip. The cell surface interaction of EGCG with immobilized
KU812 cells was measured using a SPR biosensor. EGCG was in-
jected at a concentration of 0 or 50 WM for the indicated interval in
the ¢gure. C: After treatment with or without MLCD, KU812 cells
were cultured with EGCG for 24 h. Then, the cells were lysed with
cold 1% Triton X-100 followed by a sucrose gradient centrifugation.
Recovered raft fractions were subjected to HPLC analysis, and the
chromatograms are shown.
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follows: The elevation of the SPR signal (the angle value) was
observed immediately after the injection of the ligands. After
the termination of the ligand exposure, the perfusion bu¡er
was changed to the ligand-free running bu¡er, and the SPR
signal was reduced by the dissociation of ligands bound the
surface of the immobilized molecules, and the signal con-
verged to a constant level. On the other hand, this technique
has been also applied to the analysis of secondary signaling
reactions induced by the ligand exposure to the immobilized
living cells [26]. In this case, the increase in the SPR signal was
observed even after the ligand exposure, and the signal ¢nally
returned to the basal level. In the present study, SPR experi-
ments showed that the SPR signal signi¢cantly increased by
the injection of EGCG, and the SPR signal was reduced just
after the termination of the ligand exposure (Fig. 2B). The
SPR signal did not return to the base level at even 60 min
after exposure (data not shown). This signal pattern appears
to be similar to the case of binding signals rather than sec-
ondary signaling reactions of the cells. In addition, the signal
pattern was obtained in not only the living cells but also the
dead cells (data not shown). These results suggested that the
SPR signal of EGCG may be due to a result of the binding to
the plasma membrane. In the study on a disruption of lipid
rafts, the treatment with MLCD clearly decreased the binding
of EGCG, and this treatment also led to a reduced amount of
EGCG in the raft fraction isolated from MLCD-treated cells
(Fig. 2C). These results suggest that lipid rafts may be related
to the interaction between EGCG and the cell surface of
KU812 cells.
3.3. E¡ect of raft integrity on the ability of EGCG to suppress
FcORI expression
To further examine the e¡ect of MLCD on the suppression
of FcORI expression by EGCG, after MLCD treatment,
KU812 cells was incubated with EGCG for 24 h under se-
rum-free conditions. The cell surface expression of FcORI was
measured by £ow cytometric analysis using the FcORIK chain
antibody CRA-1 (Fig. 3A). In the absence of MLCD, EGCG-
treated cells showed a 32% (15.2/22.4) decrease in the value of
mean £uorescence intensity compared to the non-treated cells,
but pretreatment with MLCD reduced this suppressive e¡ect
from 32% to 16% (20.4/24.2). Furthermore, the amount of
total cellular FcORI K chain was reduced upon treatment
with EGCG, but this suppressive e¡ect was lowered by
MLCD pretreatment (Fig. 3B). These results indicated that
the ability of MLCD to abrogate the suppressive e¡ect of
EGCG on the FcORI cell surface expression may be due to
the abrogation of the reduction of total cellular FcORI K chain
expression. Taken together, this suggests that lipid rafts play
an important role in the EGCG-induced suppression of FcORI
expression.
3.4. Involvement of ERK1/2 in the suppressive e¡ect of EGCG
on FcORI expression
EGCG have been known to exert cancer-preventive e¡ects,
and tumor-associated protein kinases MAPK have been sug-
gested to be possible targets for actions of EGCG [27^29].
Thus, for elucidating the molecule which mediates the reduc-
tion of FcORI expression by EGCG, we examined the involve-
ment of MAPK. After a 25 WM EGCG treatment for 3 h, the
level of phosphorylated MAPKs were measured by immuno-
blot analysis. EGCG clearly inhibited ERK1/2 phosphoryla-
tion, slightly reduced the phosphorylation of JNK, but did
not a¡ect p38 MAPK activity (Fig. 4A). We further examined
the e¡ect of speci¢c inhibitors to the three MAPKs (PD98059
(ERK1/2), SB203580 (p38 MAPK), or SP600125 (JNK)) at a
concentration of 10 WM for 24 h on the FcORI expression.
Flow cytometric analysis showed that among the MAPK in-
hibitors, a decrease of the cell surface expression of FcORI was
observed only in PD98059-treated cells, whereas no decrease
in the level of FcORI expression upon treatment with the other
MAPK inhibitors was found (Fig. 4B). These results sug-
gested that the downregulation of ERK1/2 activity is the im-
portant event for decreasing FcORI expression.
We also examined the e¡ect of PD98059 on the level of the
total cellular protein and mRNA expression of FcORI K chain.
Both protein and mRNA levels of FcORI K chain decreased
upon treatment with PD98059 (Fig. 4C,D). In addition, the
FcORI Q mRNA levels in PD98059-stimulated cells was shown
to be signi¢cantly reduced. These results suggested that the
suppressive e¡ect of PD98059 on the cell surface expression of
FcORI is related to the downregulation of the expression of
Fig. 3. MLCD pretreatment prevents EGCG from suppressing
FcORI expression. A: After treatment with 5 mM MLCD for 45
min, KU812 cells were stimulated with EGCG at 25 WM for 24 h.
Then, the cells were stained with CRA-1 (solid line) or mouse
IgG2b (thin line) as an isotype-matched negative control. The £uo-
rescence intensity was determined using the FACSCalibur. The val-
ue indicated in the ¢gure is the mean £uorescence intensity of
CRA-1. The vertical line in the ¢gure indicates the peak point for
CRA-1 in the non-treated cells. B: MLCD-pretreated (+) or non-
treated (3) KU812 cells were cultured with (+) or without (3) 25
WM EGCG under serum-free conditions for 24 h. Immunoblot anal-
ysis was performed using the anti-FcORI K chain antibody CRA-1.
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FcORI K and Q chain genes. Moreover, these results and the
fact that EGCG was able to decrease the mRNA expression
of both FcORI K and Q chains as previously reported [3] sug-
gest a possibility that the FcORI-suppressive e¡ect of PD98059
may mimic EGCG.
3.5. Disruption of lipid rafts cancel the inhibition of the ERK1/
2 phosphorylation by EGCG
To clarify whether or not the reductive action of ERK1/2
phosphorylation by EGCG is transduced through the inter-
action with the lipid rafts, after treatment with MLCD, the
cells were cultured with EGCG for 3 h and the level of phos-
phorylated ERK1/2 was determined by immunoblotting. This
analysis revealed that EGCG reduced the level of ERK1/2
phosphorylation in the cells without MLCD, but pretreatment
with MLCD canceled this inhibitory e¡ect (Fig. 5). Since the
total level of ERK1/2 was not a¡ected by MLCD pretreat-
ment, lowering the e¡ect of EGCG was not responsible for
enhancing total amounts of ERK1/2 by MLCD. Therefore,
these results indicated that lipid rafts were the principal loca-
tion for transducing the suppressive e¡ect of EGCG on
ERK1/2 phosphorylation.
Fig. 4. E¡ect of MAPK speci¢c inhibitors on the cell surface expression of FcORI. A: KU812 cells were treated with 25 WM EGCG for 3 h.
Each MAPK was separated on a 10% SDS^PAGE and immunoblotted with the anti-phosphorylated ERK1/2, p38 MAPK, and JNK antibod-
ies. The detection of L-actin was simultaneously performed as a gel loading control. B: KU812 cells were stimulated with each MAPK speci¢c
inhibitor at 10 WM for 24 h under serum-free conditions. Then, the cells were stained with CRA-1 (solid line) or mouse IgG2b (thin line) as
the isotype-matched negative control. The £uorescence intensity was determined using the FACSCalibur. The value indicated in the ¢gure is
the mean £uorescence intensity for CRA-1. The vertical line in the ¢gure indicates the peak point for CRA-1 in the non-treated cells. C:
KU812 cells were treated with 10 WM PD98059 for 24 h. Immunoblot analysis was performed using the anti-FcORI K chain antibody CRA-1.
D: After treatment with 10 WM PD98059 for 24 h, total RNA was isolated from the cells. FcORI K, Q and G3PDH mRNA were analyzed by
RT-PCR. Southern blotting using speci¢c probes for FcORI K, Q or G3PDH was performed to assess the PCR products.
Fig. 5. MLCD pretreatment cancels the inhibitory e¡ect of EGCG
on the ERK1/2 activation. After treatment with 5 mM MLCD for
45 min, KU812 cells were stimulated with 25 WM EGCG for 3 h.
ERK1/2 was separated on a 10% SDS^PAGE and immunoblotted
with the anti-phosphorylated ERK1/2 antibody. Shown in the lower
panel are protein levels from the same ¢lter blotted again with the
anti-ERK1/2 antibody.
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4. Discussion
EGCG has been found to inhibit epidermal growth factor-
or platelet-derived growth factor-mediated tumor cell growth
by reducing the autophosphorylation of their receptors [8],
and both of these receptors were observed in lipid rafts
[14,15]. The formation of senile plaques containing the L amy-
loid peptide (AL) derived from the amyloid precursor protein
(APP) is an invariant feature of Alzheimer’s disease. It has
been demonstrated that APP interacts with lipid rafts and
which are critically involved in regulating AL generation
[30]. AL has been known to be toxic to neurons in rat primary
hippocampal cultures [31], and such neurotoxicity have been
shown to be attenuated by treatment with EGCG [32]. These
circumstances have fueled interest in the role of lipid rafts as a
platform for researching the function of EGCG, but there has
been no direct data proving the relationship of EGCG with
lipid rafts.
In this study, more of EGCG was found in the raft fraction
(Triton X-100-resistant pool) than the non-raft fraction, indi-
cating that EGCG is sensitive to cholesterol depletion. A cho-
lesterol-depleted study showed a remarked reduction of
EGCG in the raft fraction. Although total cellular level of
EGCG was decreased upon treatment with MLCD, there
was little change in the amount of EGCG in the non-raft
fraction after cholesterol depletion (data not shown). The
measurements of EGCG contents have been repeatedly per-
formed and representative data have been shown. These ob-
servations showed that cholesterol depletion increased in the
partitioning rate of EGCG from the raft fraction to the non-
raft fraction. These facts may suggest a preference of EGCG
for a certain lipid phase in the original membrane, but it
might also re£ect partitioning of EGCG during the Triton
X-100 incubation. Although results of HPLC analysis may
show the amount of EGCG in all cellular membrane, not
just plasma membrane, SPR analysis directly re£ects the in-
teraction of EGCG with the cell surface, that is, plasma mem-
brane. The SPR signal shown here was reduced by 50% after
cholesterol depletion, indicating that the amount of EGCG
bound to the cell surface, plasma membrane, of the immobi-
lized cells decreases by half of intact level. The extent of
EGCG’s binding to plasma membrane was indeed correlated
with the level of EGCG in the raft fraction. In addition, the
cholesterol depletion did not in£uence the amount of phos-
pholipid in the immobilized cells (data not shown). These
results suggest that the reduced SPR signal after cholesterol
depletion does not result from a reduction of phospholipid,
but it may be due to a decrease in the amount of EGCG
bound to lipid rafts on the cell surface. This raised a possi-
bility that the target of EGCG may be not only lipid compo-
nents such as cholesterol, but also a membrane protein in lipid
rafts on the cell surface. Now, the investigation for the cell
surface molecule acting as an EGCG receptor, which can
mediate the FcORI-suppressive e¡ect, is proceeding.
The FcORI of the basophilic RBL-2H3 cells in resting state
has been reported to be not associated with lipid rafts, and the
receptor aggregation induces a weak association with rafts
[20]. Our results that the expression of FcORI in resting state
was not a¡ected by cholesterol depletion may suggest a pos-
sibility that non-aggregated FcORI does not associate with
lipid rafts on the surface of human basophilic KU812 cells.
The cholesterol depletion also induced the inability of EGCG
to suppress the FcORI expression. This treatment did not af-
fect the FcORI expression, but caused a signi¢cant reduction
of the amount of EGCG in the lipid rafts, which may be due
to a lowered binding of EGCG to the cells. Therefore, this
reduction of EGCG bound to lipid rafts may cause the dimin-
ishing of the FcORI-suppressive signal. However, it is not able
to exclude the possibility that the lowering of cholesterol dur-
ing 24 h may have induced many changes in the cell that are
unrelated to the structure and function of lipid rafts, and
further investigations are necessary. Taken together, these re-
sults suggest that lipid rafts play a critical role in EGCG’s
ability to suppress FcORI expression. As far as we know, this
¢nding is the ¢rst evidence proving direct linkage of EGCG
functions with the lipid rafts.
Recently, EGCG has been reported to have a modulatory
e¡ect on ERK1/2 as well as other MAPKs, p38 MAPK and
JNK, cascades [10,29,33]. However, neither a p38 MAPK nor
JNK speci¢c inhibitor directly a¡ected the cell surface expres-
sion of FcORI, nor the inhibitors were able to cancel EGCG’s
ability to suppress FcORI expression (data not shown). This
indicates that the decrease in FcORI expression by EGCG was
independent of the p38 MAPK and JNK cascades. On the
other hand, our experiments revealed that EGCG had an in-
hibitory e¡ect on ERK1/2 phosphorylation, and the ERK1/2
speci¢c inhibitor PD98059 suppressed FcORI expression. This
FcORI-suppressive e¡ect was observed after more than a 12-h
treatment similar to EGCG, and further PD98059 clearly re-
duced the level of phosphorylated ERK1/2 from 3 to 12 h
after the addition, which closely mirrored EGCG’s ability to
induce a decrease in ERK1/2 phosphorylation (data not
shown). An incubation of 3 or 6 h with EGCG or PD98059
indeed a¡ected ERK1/2 phosphorylation, but there was no
change in the FcORI expression. PD98059 treatment also low-
ered the level of FcORI K and Q mRNA as previously reported
for EGCG [3]. These ¢ndings suggest that at least a 12-h
sustained reduction of ERK1/2 phosphorylation was required
for downregulation of the FcORI expression by EGCG. In
mast cells and basophils played a central role in the FcORI-
mediated allergic reaction, the involvement of MAPKs in cy-
tokine production, release of chemical mediators, cell survival
and regulation of apoptosis have been indicated [34^36].
However, with regard to FcORI expression, there is very little
information concerning the MAPK signal pathways. On the
other hand, the ERK1/2 activation has been reported to de-
pend on lipid rafts [37,38]. In consideration of this report and
our observations that EGCG associates with lipid rafts, it is
not unexpected that the raft disruption prevents EGCG from
inhibiting the ERK1/2 phosphorylation. These ¢ndings may
also provide new insights, as to the involvement of lipid rafts,
into the mechanism for the inhibition of ERK1/2 signaling by
EGCG.
In the present study, we observed that the disruption of
lipid rafts inhibited the suppressive e¡ect of EGCG on the
ERK1/2 activation. This is thought to be direct evidence
showing that lipid rafts play a critical role in EGCG’s ability
to reduce ERK1/2 phosphorylation. In addition, it was specu-
lated that diminishing the cascade signals may be caused by a
lowering of the interaction between EGCG with the lipid
rafts, resulting in a reduced suppression of FcORI expression.
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